DEFB133
Beta-defensin 133
Also known as: DB133_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for DEFB133 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
61 residues, UniProt reviewed canonical sequence.
>Q30KQ1|DEFB133
1 MKIHVFLFVL FFFLVPIATR VKCAVKDTYS CFIMRGKCRH ECHDFEKPIG FCTKLNANCY
61 MLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DEFB133 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.9
- gnomAD pLI
- 0.28
- gnomAD missense Z
- 0.6
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DEFB133 as an antibody target. Whether an autoantibody or antibody against DEFB133 could matter depends on whether native DEFB133 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DEFB133 is annotated as secreted, so native DEFB133 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label DEFB133 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...